(NewsDirect)
Noxopharm Ltd(ASX:NOX, OTC:NOXOF) chief executive officer Dr Gisela Mautner joinsProactive alongside Associate Professor Michael Gantier from theHudson Institute of Medical Research to discuss their partnering onthe SOF-VAC mRNA vaccine enhancer. They’re investigating thepotential for Sofra oligonucleotides to limit the inflammatory sideeffects associated with mRNA therapeutics and vaccines. They say theability of the oligonucleotides to reduce inflammation opens up newpossibilities for the treatment of many diseases.
Noxopharm is aninnovative Australian biotech company discovering and developing noveltreatments for cancer and inflammation, as well as improving mRNAvaccines.
It hasthree active drug development programs: two innovative technologyplatforms – Sofra™ (mRNA vaccines, inflammation and autoimmunity)and Chroma™ (oncology) which provide the basis for activedevelopment of a growing pipeline of new proprietary drugs, as well asits clinical drug candidate Veyonda®.
The company has unique proprietary technologyaimed at making mRNA vaccines safer to take by reducing side effectswhile reducing manufacturing costs for vaccine producers.
Noxopharm also has a major shareholding inthe US biotech company Nyrada Inc (ASX:NYR), which is active in theareas of drug development for cardiovascular and neurologicaldiseases.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.